Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma

NCT00942331 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00942331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00942331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Completed
Start date
July 15, 2009
Completion date
June 15, 2021
Enrollment
506 (actual)
Sites
873

Conditions

As the registry lists them; a condition with its own page is linked.

advanced urothelial carcinoma, metastatic bladder urothelial carcinoma, metastatic prostate carcinoma, metastatic renal pelvis urothelial carcinoma, metastatic ureter urothelial carcinoma, metastatic urethral urothelial carcinoma, metastatic urothelial carcinoma, stage iv bladder urothelial carcinoma ajcc v7, stage iv prostate cancer ajcc v7, stage iv renal pelvis cancer ajcc v7, stage iv ureter cancer ajcc v7, stage iv urethral cancer ajcc v7, unresectable urothelial carcinoma